博安生物(06955)发布中期业绩 股东应占溢利2051.4万元 同比减少66.74%

Core Points - The company reported a revenue of 393 million RMB for the six months ending June 30, 2025, representing an increase of 8.39% year-on-year [1] - Shareholder profit attributable to the company was 20.514 million RMB, a decrease of 66.74% compared to the previous year [1] - Basic earnings per share were 0.04 RMB [1] Revenue Analysis - The increase in revenue was primarily driven by the sales growth of products (博优诺®, 博优倍®, and 博洛加®), which rose by 15.9% to 385 million RMB compared to the six months ending June 30, 2024 [1]